• Explore /
  • Poster
  • / Evaluation of predictive biomarkers for nivolumab in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) from the CheckMate-025 (CM-025) trial.

Evaluation of predictive biomarkers for nivolumab in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) from the CheckMate-025 (CM-025) trial.

Abstract Video & Slides Poster

Authors

null

Miriam Ficial

Brigham and Women's Hospital, Boston, MA

Miriam Ficial , Opeyemi Jegede , Miriam Sant'Angelo , Sonia Moreno , David A. Braun , Megan Wind-Rotolo , Jean-Christophe Pignon , Paul J. Catalano , Maxine Sun , Eliezer Mendel Van Allen , Gordon J. Freeman , Arlene Sharpe , F. Stephen Hodi , Robert J. Motzer , Catherine J. Wu , Michael B. Atkins , David F. McDermott , Sachet A. Shukla , Toni K. Choueiri , Sabina Signoretti

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Discussion Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Kidney Cancer

Citation

J Clin Oncol 38: 2020 (suppl; abstr 5023)

DOI

10.1200/JCO.2020.38.15_suppl.5023

Abstract #

5023

Poster Bd #

92

Abstract Disclosures

Similar Posters

First Author: Jean-Christophe Pignon

First Author: Jean-Christophe Pignon

First Author: Nourhan El Ahmar

First Author: Mathilde Cancel